Abbott launches the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain

The u.s. food and drug administration (fda) approved abbott's eterna™ spinal cord stimulation (scs) system for the treatment of chronic pain this neuromodulation device provides an optimized experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable scs systems §1,2,3 abbott park, ill., dec. 19, 2022 /prnewswire/ -- abbott (nyse: abt) today announced the u.s. food and drug administration (fda) approval of the company's eterna™ spinal cord stimulation (scs) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.
ABT Ratings Summary
ABT Quant Ranking